Gilead pass­es on ful­ly ac­quir­ing Pi­o­nyr, as eyes now turn to Tizona, a fel­low sum­mer 2020 buy­out op­tion

Gilead and Pi­o­nyr Im­munother­a­peu­tics, a biotech try­ing to fol­low up on the first gen­er­a­tion of check­point in­hibitors, have “mu­tu­al­ly agreed” on a rewrite to their …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER